168 related articles for article (PubMed ID: 38288815)
1. An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021).
Vishakha S; Navneesh N; Kurmi BD; Gupta GD; Verma SK; Jain A; Patel P
Anticancer Agents Med Chem; 2024; 24(8):590-626. PubMed ID: 38288815
[TBL] [Abstract][Full Text] [Related]
2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract][Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
4. Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications.
Tamatam R; Mohammed A
Eur J Med Chem; 2024 Jun; 272():116441. PubMed ID: 38759455
[TBL] [Abstract][Full Text] [Related]
5. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
Roskoski R
Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
[TBL] [Abstract][Full Text] [Related]
6. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
7. New pharmaceuticals approved by FDA in 2020: Small-molecule drugs derived from amino acids and related compounds.
Liu A; Han J; Nakano A; Konno H; Moriwaki H; Abe H; Izawa K; Soloshonok VA
Chirality; 2022 Jan; 34(1):86-103. PubMed ID: 34713503
[TBL] [Abstract][Full Text] [Related]
8. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
Olivier T; Haslam A; Prasad V
JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
[TBL] [Abstract][Full Text] [Related]
11. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications.
Cristina Mendonça Nogueira T; Vinicius Nora de Souza M
Bioorg Med Chem; 2021 Sep; 46():116340. PubMed ID: 34416511
[TBL] [Abstract][Full Text] [Related]
12. A systematic analysis of FDA-approved anticancer drugs.
Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
[TBL] [Abstract][Full Text] [Related]
13. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.
Sochacka-Ćwikła A; Mączyński M; Regiec A
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408658
[TBL] [Abstract][Full Text] [Related]
14. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Wang S; Yuan XH; Wang SQ; Zhao W; Chen XB; Yu B
Eur J Med Chem; 2021 Mar; 214():113218. PubMed ID: 33540357
[TBL] [Abstract][Full Text] [Related]
15. Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020.
Kooijman JJ; van Riel WE; Dylus J; Prinsen MBW; Grobben Y; de Bitter TJJ; van Doornmalen AM; Melis JJTM; Uitdehaag JCM; Narumi Y; Kawase Y; de Roos JADM; Willemsen-Seegers N; Zaman GJR
Front Oncol; 2022; 12():953013. PubMed ID: 36185300
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review.
Sangwan K; Sharma V; Goyal PK
Curr Mol Med; 2023 Jun; ():. PubMed ID: 37350009
[TBL] [Abstract][Full Text] [Related]
17. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
18. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.
Jiang DM; Chan KKW; Jang RW; Booth C; Liu G; Amir E; Mason R; Everest L; Elimova E
Cancer Med; 2019 Apr; 8(4):1584-1593. PubMed ID: 30848108
[TBL] [Abstract][Full Text] [Related]
19. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.
Tong JTW; Harris PWR; Brimble MA; Kavianinia I
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641391
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to watch in 2020.
Kaplon H; Muralidharan M; Schneider Z; Reichert JM
MAbs; 2020; 12(1):1703531. PubMed ID: 31847708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
